

PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to provide information unless it contains a valid OMB control number

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/590,445 - Conf. # 6734
				Filing Date	August 24, 2006
				First Named Inventor	Michael Jung
				Art Unit	1614
				Examiner Name	James D. Anderson
Sheet	3	of	7	Attorney Docket Number	58086-235854

C10	Keown et al., <i>Methods in Enzymology</i> , 185:507-527 (1990).
C11	Mansour et al., <i>Nature</i> , 339:348-352 (1988).
C12	Muller et al., 1991, <i>Mol. & Cell. Bio.</i> 11:1763.
C13	Uriab et al., <i>Proc. Natl. Acad. Sci. USA</i> , 77:4216 (1980).
C14	Stinchcomb et al., <i>Nature</i> , 282:20 (1979).
C15	Kingsman et al., <i>Gene</i> , 7: 141 (1979).
C16	Tschumper et al., <i>Gene</i> , 10: 157 (1980).
C17	Jones, <i>Genetics</i> , 85:23 (1977).
C18	Feldman, B.J. & Feldman, D. The development of androgen independent prostate cancer. <i>Nat Rev Cancer</i> 1, 34-45 (2001).
C19	Getmann, E.P. Molecular biology of the androgen receptor. <i>J Clin Oncol</i> 20, 6881-15 (2002).
C20	Balk, C.P. Androgen receptor as a target in androgen independent prostate cancer. <i>Urology</i> 60, 132-8; discussion 138-9 (2002).
C21	Taplin, M.E. et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. <i>Cancer Res</i> 59, 2511-5 (1999).
C22	Taplin, M.E. et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. <i>J Clin Oncol</i> 21, 2673-8 (2003).
C23	Veeckrapi, T. et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. <i>Nat Genet</i> 9, 401-6 (1995).
C24	Taplin, M.E. et al. Mutation of the androgen receptor gene in metastatic androgen independent prostate cancer. <i>N Engl J Med</i> 332, 1393-8 (1995).
C25	Veloschoite, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. <i>Biochem Biophys Res Commun</i> 173, 534-40 (1990).
C26	Matias, P.M. et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. <i>J Med Chem</i> 45, 1439-46 (2002).
C27	Craft, N., Shostak, Y., Carey, M. & Sawyers, C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. <i>Nat Med</i> 5, 280-5 (1999).
C28	Gioeli, D. et al. Androgen receptor phosphorylation: Regulation and identification of the phosphorylation sites. <i>J Biol Chem</i> 277, 29304-14 (2002).
C29	Kato, S. et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. <i>Science</i> 270, 1491-4 (1995).
C30	Font de Mora, J. & Brown, M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. <i>Mol Cell Biol</i> 20, 5041-7 (2000).
C31	Tremblay, A., Tremblay, C.B., Labrie, F. & Giguere, V. Ligand independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. <i>Mol Cell</i> 3, 513-9 (1999).

Examiner Signature	/Savitha Rao/	Date Considered	03/23/2010
--------------------	---------------	-----------------	------------